Beijing, China, September 5, 2025 — As one of Africa's largest and most influential pharmaceutical exhibitions and conferences, Pharmaconex 2025 was grandly held from September 1 to 3 at Egypt International Exhibition Center. The event attracted over 350 exhibitors from more than 40 countries, as well as more than 13,500 professional visitors, to explore innovations and opportunities across the entire pharmaceutical value chain, including APIs, formulations, equipment, and packaging. At this international pharmaceutical event, Gan & Lee Pharmaceuticals. (hereinafter referred to as Gan & Lee, Stock Code: 603087.SH), a leading Chinese company in diabetes treatment, showcased its insulin product portfolio, supporting delivery devices, and cutting-edge pipeline innovations, contributing Chinese expertise to global health.

At the exhibition, Gan & Lee presented six core insulin products covering long-acting, rapid-acting, premixed, and human insulin injections, along with delivery devices such as prefilled pens and reusable pens. With bioequivalence and safety comparable to originator drugs, the company's insulin products have received widespread recognition in global markets. Notably, Gan & Lee's production lines for the drug substance, cartridges, and prefilled pens of glargine, aspart, and lispro insulin, which successfully passed the EMA GMP inspection in 2024, have laid a solid foundation for global product quality and accessibility.

In addition, Gan & Lee announced the latest research results for its innovative drugs under development, including Bofanglutide (GZR18) injection and long-acting weekly insulin GZR4 injection, aiming to provide global patients with multi-level solutions ranging from basic therapy to complex glycemic management. Through its unique framework of "independent R&D + full-chain layout + localized collaboration," Gan & Lee presented a comprehensive strategy for diabetes treatment on the global stage.

During the exhibition, Gan & Lee's product portfolio and innovative achievements attracted numerous pharmaceutical professionals, distributors, and company representatives from Africa and the Middle East. Visitors showed strong interest in the company's comprehensive product portfolio and advanced production quality control system, while engaging in in-depth discussions on potential collaborations. Through these communications, the company has successfully secured preliminary cooperation intentions with multiple organizations, laying a solid foundation for further market penetration in the region.

As a core country in the MENA region, Egypt's pharmaceutical market has significant regional influence. According to the International Diabetes Federation (IDF) 2024 data, the prevalence of diabetes among people aged 20–79 in the MENA region reaches 19.9%, the highest globally, with a total of 84.7 million living with the condition. To address this severe challenge, Gan & Lee is focusingits efforts on Egypt to develop a "key-anchor-driven regional expansion model," which not only enhances drug accessibility effectively but also paves the way for further expanding into neighboring markets.

From China to the world, every step of Gan & Lee's journey safeguards global patient health with high-quality products. In the future, Gan & Lee will continue to focus on patient needs, promote the sustainable development of affordable, high-quality Chinese medical solutions, and deepen international cooperation in comprehensive diabetes management and innovative treatments, continuously contributing Chinese value to global health and well-being.

About Pharmaconex

Pharmaconex Egypt is a mature pharmaceutical industry exhibition in North Africa and the Middle East and one of the largest professional pharmaceutical exhibitions in Africa. It plays an important role in regional pharmaceutical industry exchanges. The exhibition focuses on pharmaceutical raw materials, manufacturing machinery, and laboratory equipment. Since its inception, it has been successfully held 11 times, attracting numerous pharmaceutical companies and professional visitors from around the world, creating business opportunities for both buyers and sellers.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.